Opinion: A truce in the stem cell wars?
By Richard Hayes,
San Francisco Examiner
| 11. 24. 2006
The contentious midterm elections clearly left a mark on the politics of stem cell research, but it’s not clear what the mark signifies. Missouri’s closely watched stem cell initiative barely squeaked by with 51 per cent of the vote, despite a $30 million campaign financed almost entirely by a single wealthy couple. And in nine congressional races identified as high priority by stem cell research advocates, the stem cell candidate won in only four.
At the same time, at least 60 percent of all races in which stem cell research was an issue — including high-profile races for Congress, the Senate, and governorships — were won by the candidate supporting the research. And there’s no denying the frenzied TV and YouTube campaigning by partisans on all sides reinforced the identity of "stem cells" as an iconic trope of the culture wars.
Incoming Democratic House Speaker Nancy Pelosi has pledged a vote on federal stem cell funding "within the first 100 hours" of the new Congress. It appears there are now enough votes in the Senate to override a presidential veto...
Related Articles
By Nicholas Wade, The New York Times | 04.30.2026
“J. Craig Venter” via Wikimedia Commons licensed under CC by 2.5
J. Craig Venter, a scientist and entrepreneur who raced to decode the human genome, died on Wednesday in San Diego. He was 79.
His death was announced by...
By Susan Dominus, The New York Times Magazine | 04.27.2026
Why are babies born young? The most natural phenomenon on earth is actually hard to explain — at least on a cellular level. Consider this problem: The components of conception are old. When a woman gets pregnant, she has...
By Jonathan Basile, Los Ángeles Review of Books | 04.29.2026
WILLIAM BATESON, a foundational figure in the science of genetics at the turn of the last century, once recounted the response of a Scottish soldier to one of his public lectures: “Sir, what ye’re telling us is nothing but Scientific...
By Rob Stein, NPR | 04.23.2026
The Food and Drug Administration approved the first gene therapy to restore hearing for people who were born deaf.
The decision, while only immediately affecting people born with a very rare form of genetic deafness, is being hailed as...